Here are four things to know.
1. The FDA approved 46 new drugs, agents or therapeutic biologics in 2017. Sixteen of the 46, or about 35 percent, are classified as personalized medicines.
2. In 2016, 13 of 45 new drug approvals were personalized medicines.
3. This marks the first time in history that the number of personalized medicines approved in a year topped 30 percent. Ten years ago, personalized medicines accounted for less than 10 percent of new drug approvals.
4. In 2017, the FDA approved the first gene therapy for use in the U.S. Now, three gene therapies have been approved for use.
To read the full report, click here.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
FDA approves treatment for digestive tract cancers: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.